Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

58.68 +0.55 (+0.95%)
Streaming Delayed Price Updated: 1:23 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,049,931
Open 58.36
Bid (Size) 58.66 (400)
Ask (Size) 58.70 (300)
Prev. Close 58.13
Today's Range 57.78 - 58.96
52wk Range 50.01 - 86.74
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive... 
Via MarketBeat
News headline image
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-26.3%
-26.3%
1 Month
+6.6%
+6.6%
3 Month
-21.9%
-21.9%
6 Month
-21.9%
-21.9%
1 Year
-3.0%
-3.0%

More News

Read More
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
Via The Motley Fool
Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Via The Motley Fool
Topics ETFs World Trade
News headline image
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Via The Motley Fool
News headline image
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
Via The Motley Fool
News headline image
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Ionis (IONS) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis reports second quarter 2026 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Cathie Wood Just Bet Big on This Biotech Stock ↗
Via The Motley Fool
Topics ETFs
News headline image
Ionis to hold second quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Via MarketBeat
News headline image
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 58.68
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 09/04/26 01:23 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 8.32B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.